Long term use of curcumin in two smoldering multiple myeloma patients


J Hematol Malign. 2013;3(1):18-23


Smoldering Multiple Myeloma (SMM) is an asymptomatic plasma cell disorder. During the first 5 years, SMM has an overall risk of progression to multiple myeloma at a rate of 10% per year. Compared to monoclonal gammopathy of undetermined significance (MGUS), SMM is a more advanced pre-malignant condition.

Due to highly unpredictable clinical course of SMM, early intervention involving reducing the abnormal protein load, the abnormal serum-free light chain ratio and the % plasma cell load is the method of approach.

Curcumin has been found to be effective against MGUS and SMM due to its anti-myeloma cell activity, which has been substantiated in several in vitro and in vivo studies. Researchers have also shown that oral Curcumin was effective against MGUS and SMM, in a select group of patients.


To study the long term use of Curcumin in two male patients with plasma cell dyscrasias.


Study Design:

  • This case report involved two male Caucasian patients (Age: 47 and 66 years) who were previously enrolled into a 9-month clinical trial of oral Curcumin in patients with plasma cell dyscrasias, and thereafter elected to continue on the same regimen of oral curcumin, for a period of 2 years
  • Both Patient #1 and #2 were diagnosed with SMM as per International Myeloma Working Group (IMWG) classification, who showed overall clinical improvement after 9 months of Curcumin therapy during previous clinical trial
  • After completion of the trial, these two patients were elected to continue with Curcumin therapy for 2 more years on a maintenance dose of 6g/day
  • At the end of 2 years, blood tests and a bone marrow biopsy were performed in order to determine influence of Curcumin on disease progression


Results and Discussion:

  • Both patients showed continued decrease in paraprotein, total protein, gamma-globulin and IgG
  • CD 138+ plasma cells in bone marrow of both patients was reduced by 50%
  • Patient #1 demonstrated reduction in free light chain ratio (rFLC) from 26.5 to 4.5 after 2 years of treatment
  • Other parameters like β-2-microglobulin, lactate dehydrogenase, calcium, albumin, haemoglobin, creatinine and parathyroid hormone levels remained same in both patients when evaluated after 2 years of treatment



A significant improvement in a number of markers of disease activity with no side-effects from long term, high dose Curcumin therapy was witnessed. Hence, it is suggested that SMM patients may be benefited from long term Curcumin therapy without any toxicity.

About Sabinsa

Sabinsa Corporation is a manufacturer, supplier and marketer of herbal extracts, cosmeceuticals, minerals, dietary supplements and specialty fine chemicals for the nutritional, cosmetic, pharmaceutical and food industries.

Read More..


Sabinsa Corporation

20 Lake Drive 

East Windsor,

NJ 08520, USA

Tel: +1 732 777 1111

Fax: +1 732 777 1443

This email address is being protected from spambots. You need JavaScript enabled to view it.


Contact Presence